Precision Medicine for Indolent Systemic Mastocytosis (PRISM)
NCT07757893 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 25
Last updated 2026-08-11
Summary
This study is being done to better understand how symptoms of Systemic Mastocytosis (SM) relate to biological signals and to better understand how different treatments affect these signals.
Conditions
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Thanai Pongdee, MD · Mayo Clinic
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-09-09
- Primary Completion
- 2027-08-31
- Completion
- 2027-08-31
Countries
- United States
Study Locations
More Related Trials
-
Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
NCT04276233 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
NCT07264959 ·Status: RECRUITING
-
Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders
NCT06068829 ·Status: UNKNOWN
-
A Real World Study About PMN
NCT06893328 ·Status: RECRUITING
-
Safety and Tolerability of Rituximab in Neuromyelitis Optica
NCT00501748 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
NCT03770273 ·Status: COMPLETED ·Phase: PHASE2
-
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
NCT07079423 ·Status: RECRUITING ·Phase: PHASE2
-
Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
NCT02197767 ·Status: COMPLETED ·Phase: PHASE2
-
Maintenance Plasma Exchange for Neuromyelitis Optica
NCT01500681 ·Status: COMPLETED
-
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT06180278 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance
NCT00588822 ·Status: TERMINATED ·Phase: PHASE2
-
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
NCT04182984 ·Status: RECRUITING
-
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800 ·Status: RECRUITING ·Phase: PHASE3
-
Treatment of IgG4-Related Disease With Revlimid and Rituximab
NCT02705638 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
NCT00005571 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab in Membranous Nephropathy
NCT00425217 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
NCT07100990 ·Status: RECRUITING ·Phase: PHASE3
-
Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)
NCT02966717 ·Status: UNKNOWN ·Phase: PHASE2
-
An Outcome Analysis of Primary Membranous Nephropathy
NCT06242327 ·Status: RECRUITING
-
In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO
NCT04629274 ·Status: COMPLETED ·Phase: NA
-
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
NCT06958939 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
NCT05137496 ·Status: UNKNOWN ·Phase: PHASE3
-
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
NCT00106184 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
NCT01673009 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
NCT07047690 ·Status: RECRUITING ·Phase: PHASE2